Axonics Modulation Technologies Company Overview

Axonics Modulation Technologies logo
Axonics Modulation Technologies
Axonics Modulation Technologies primary media

About Axonics Modulation Technologies

Axonics Modulation Technologies (NASDAQ:AXNX) specializes in developing and commercializing innovative neuromodulation products aimed at treating bladder and bowel dysfunction. The company's primary focus is on improving the lives of patients suffering from these conditions through advanced medical technology. Axonics has dedicated itself to research and development to continuously enhance its product offerings, aligning with its objective to set new standards in the neuromodulation industry. Their efforts are encapsulated in their Sacral Neuromodulation (SNM) system, a notable project designed to offer a minimally invasive solution to patients, showcasing the company's commitment to innovation and quality healthcare solutions.

What is Axonics Modulation Technologies known for?

Snapshot

2012
Year founded
665
Employees
Irvine, United States
Head office
Loading Map...

Operations

All Locations
Irvine, US

Produtos e/ou serviços de Axonics Modulation Technologies

  • Sacral neuromodulation systems for bladder and bowel control.
  • Rechargeable sacral neuromodulation (SNM) system designed for a 15-year life.
  • Non-rechargeable SNM system offering a low-maintenance treatment option.
  • Advanced programming and patient remote control for personalized therapy management.
  • Innovative urethral bulking agent for stress urinary incontinence.
  • Comprehensive patient support services including education and training.

equipe executiva do Axonics Modulation Technologies

  • Mr. Raymond W. CohenCEO & Director
  • Ms. Kari KeeseChief Financial Officer
  • Mr. Rinda K. SamaChief Operating Officer
  • Dr. John Woock Ph.D.Executive VP, Chief Marketing & Strategy Officer
  • Mr. Alfred J. Ford Jr.Chief Commercial Officer
  • Mr. Guangqiang Jiang Ph.D.Chief Technology Officer
  • Mr. Neil BhalodkarVice President of Investor Relations
  • Mr. Aaron PettitGeneral Counsel & Chief Compliance Officer
  • Mr. Michael V. Williamson Esq., J.D.Senior VP, General & IP Counsel
  • Dr. Karen L. Noblett M.A.S., M.D.Chief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.